MN MPJE cheat sheet

Federal CSA (21 U.S.C. §801 et seq.; 21 C.F.R. Parts 1300-1321) establishes scheduling, registration, recordkeeping, and dispensing rules; DEA enforces.

Minnesota's Pharmacy Practice Act is Minn. Stat. ch. 151, with implementing rules at Minn. R. ch. 6800; the Minnesota Board of Pharmacy licenses, inspects, and disciplines.

Minnesota's controlled substance statute is Minn. Stat. ch. 152; conduct violating it can be prosecuted criminally in addition to Board discipline.

Federal law is a floor: a state may impose stricter requirements (mandatory PDMP review, shorter prescription validity) but may not authorize what federal law forbids.

Minn. Stat. §62J.497 requires prescriptions to be transmitted electronically, with statutory exceptions for technical failure, certain care settings, and granted waivers.

Minn. Stat. §§144.291-.298 (Health Records Act) governs consent, access, and release of patient records; where stricter than HIPAA, the stricter rule controls.

Minn. Stat. §152.126 creates the Minnesota Prescription Monitoring Program; access is limited to prescribers, dispensers, the patient, and authorized investigators.

Board discipline proceeds as a contested case under Minn. Stat. ch. 14; available sanctions include corrective action, civil penalties, suspension, and revocation.

Schedule II: no refills; each dispensing requires a new prescription; a partial-fill remainder must be supplied within 30 days of the original prescription date.

Schedule III-V: up to five refills within six months of the issue date; no fill or refill is permitted after six months.

Emergency oral Schedule II: a pharmacist may dispense a limited quantity if the prescriber delivers a written or electronic prescription within seven days.

Schedule II prescriptions may be transmitted electronically only through a DEA-compliant EPCS system using identity proofing and two-factor authentication.

Minnesota dispensers must report each controlled substance dispensing to the PMP by the next business day after dispensing (Minn. Stat. §152.126).

Theft or significant loss: notify DEA in writing (Form 106) within one business day of discovery, retain a copy, and notify the Board of Pharmacy.

Inventory: initial inventory on the date registration begins, then a biennial inventory every two years; inventory records retained two years.

Pharmacists may dispense naloxone under Minnesota's statewide protocol without a patient-specific prescription; the statute grants civil and criminal immunity for good-faith action.

Corresponding responsibility applies: a pharmacist may not fill a controlled substance prescription that lacks a legitimate medical purpose or is outside usual professional practice.

A valid prescription must include patient name and address, drug name, strength, dosage form, quantity, directions, date, prescriber identification, and (for controlled substances) the prescriber's DEA number.

If refills are not specified, zero refills are authorized; the pharmacist may not extend refills beyond what the prescriber authorized.

Generic substitution is permitted unless the prescriber indicates dispense-as-written or the patient objects; the patient must be informed of the substitution.

Non-controlled prescriptions may be transferred between pharmacies; Schedule III-V may be transferred for refill purposes with documentation; Schedule II cannot be refilled or transferred.

A pharmacy located outside Minnesota that ships, mails, or delivers prescription drugs to Minnesota patients must hold a Minnesota nonresident pharmacy license and follow Minnesota labeling and counseling rules.

DSCSA: dispensers must verify product identifiers before dispensing, quarantine suspect or illegitimate product, and retain transaction information for six years.

Dispensed drugs may not be returned to dispensing stock once they leave the pharmacy, except under narrow Board-permitted circumstances such as recalls or dispensing errors.

Minnesota permits a one-time emergency supply of a non-controlled maintenance medication when the prescriber cannot be reached, with prompt notification to the prescriber.

Pharmacist licensure requires graduation from an ACPE-accredited program, passage of NAPLEX and MPJE, completion of Board-required internship hours, and Board approval.

Pharmacist licenses renew on a biennial cycle; Minnesota requires 30 contact hours of continuing education per renewal cycle.

Pharmacy technicians must be certified by a Board-recognized certifying body and registered with the Board; they practice under pharmacist supervision.

Each pharmacy location must hold its own Minnesota pharmacy license and designate a pharmacist-in-charge responsible for legal compliance.

Pharmacy interns must be registered with the Board before practicing and may perform pharmacist duties only under pharmacist supervision.

DEA registration is facility-specific, valid for three years, and required in addition to state licensure for any handling of controlled substances.

Changes in ownership, location, or pharmacist-in-charge must be reported to the Board within the period set by Minn. R. ch. 6800; the license is not transferable.

Operating an unlicensed pharmacy or practicing without licensure is a criminal violation under Minn. Stat. ch. 151 and grounds for Board denial of licensure.

Pharmacists must offer oral counseling on every new prescription and whenever therapy changes; the patient may decline the offer.

Documentation of a declined counseling offer supports compliance; the refusal should be recorded in the patient record.

Labels must include pharmacy name, address and phone, prescription number, fill date, patient name, drug name/strength/quantity, directions, prescriber, refill information, beyond-use date or expiration, and pharmacist initials.

Auxiliary labels (for example may cause drowsiness, refrigerate, take with food) are required when the drug's characteristics or the directions make them necessary.

Federally required patient package inserts accompany estrogens, oral contraceptives, and isotretinoin (iPLEDGE), among other products.

Minnesota pharmacists may enter collaborative practice agreements with prescribers to initiate, modify, or discontinue drug therapy under written protocols.

Patients with limited English proficiency must receive labeling and counseling they can understand; interpreter services and translated labels must be used.

OBRA-90 requires an offer to counsel for Medicaid beneficiaries; Minnesota's offer-to-counsel duty applies more broadly to all patients.

Minnesota Board rules incorporate USP <795> (nonsterile), <797> (sterile), and <800> (hazardous drugs); compliance is expected for all compounding.

Nonsterile water-containing preparations: beyond-use date of 14 days or less refrigerated; nonaqueous preparations: up to 180 days at controlled room temperature.

Sterile CSP beyond-use dates depend on the USP <797> category and storage temperature; traditional low-risk limits are 48 hours room temperature, 14 days refrigerated, 45 days frozen.

Sterile compounding requires an ISO Class 5 primary engineering control located inside an ISO Class 7 buffer area, with environmental monitoring and documented garbing.

Sterile compounding personnel competency (gloved fingertip and thumb sampling, media fill) is established initially and reassessed at least every 12 months.

Hazardous drugs require a negative-pressure room, a containment ventilated enclosure, closed system transfer devices, and documented training under USP <800>.

Compounding must be for a patient-specific prescription or in limited anticipatory quantities; copying a commercially available product requires documented clinical need.

Records must include a master formulation record and a compounding record listing ingredients, sources, lot numbers, beyond-use date, and the identity of the compounder.

Controlled substance records (receipt, dispensing, inventory, destruction) must be kept at least two years and be readily retrievable for DEA and Board inspection.

Biennial inventory: exact count required for Schedule II; estimated count is acceptable for Schedules III-V unless the container holds more than 1,000 units.

DEA Form 41 documents destruction of controlled substances; DEA Form 106 documents theft or significant loss.

The prescription area must be locked and secured whenever a pharmacist is not on duty; access is limited to authorized personnel.

Storage standards: refrigerated 2-8 degrees C, frozen -25 to -10 degrees C, controlled room temperature 20-25 degrees C; excursions are documented and evaluated.

Expired, recalled, or adulterated stock must be segregated from dispensing stock and returned to the manufacturer or a reverse distributor.

Pharmacies must maintain a continuous quality improvement program that documents medication error review and resulting system changes.

Prescription records must be readily retrievable; electronic systems require backup, audit trails, and access controls.